EVER Pharma is pleased to announce the grant of an EU-wide marketing authorization of Azacitidine for the treatment of patients with myelodysplastic...

EVER Pharma is pleased to announce EU-wide marketing authorization of Pemetrexed for the treatment of patients with Malignant pleural mesothelioma and...

EVER Pharma is pleased to announce EU-wide marketing authorization of Cabazitaxel for the treatment of adult patients with metastatic prostate cancer¹...

Although the Paracelsus Medical Private University (PMU) in Salzburg and EVER Pharma are 40 kilometres apart, their relationship has just moved much...

Launched as the D-mine^® Pump, this portable micro infusion device recently received European CE approval and is currently being launched in several...

EVER Pharma Holding Ges.m.b.H (Austria) announced today that it has completed the acquisition of Amneal Deutschland GmbH, a subsidiary of Amneal...

EVER Valinject Launches Dexmedetomidine in Europe: EVER Valinject is pleased to announce the launch of the only dexmedetomidine product in Europe...

Fulvestrant EVER Pharma is the first and only available Fulvestrant in Europe at this time that can be stored at room temperature.

The launch¹ of...

EVER Pharma has closed an agreement to acquire Pharmagen, a dynamic and rapidly growing pharmaceuticals business in the Czech Republic and Slovakia...

EVER Pharma will invest more than € 100 million over the next 4 years